First Evidence of Neosaxitoxin As a Long-acting Pain Blocker in Bladder Pain Syndrome

Overview

Journal Int Urogynecol J

Publisher Springer

Specialties Gynecology & Obstetrics
Urology

Date 2015 Jan 10

PMID 25571865

Citations 10

Authors

Valentin Manriquez

Daniela Castro Caperan

Rodrigo Guzman

Michel Naser

Veronica Iglesia

Nestor Lagos

Affiliations

Soon will be listed here.

Abstract

Introduction And Hypothesis: Neosaxitoxin is a phycotoxin whose molecular mechanism of action shows a reversible inhibition of voltage-gated sodium channels at the axonal level, impeding nerve impulse propagation. This study was designed to evaluate the clinical efficacy of neosaxitoxin as a long-acting pain blocker in the treatment of bladder pain syndrome (BPS).

Methods: Five patients with a diagnosis of BPS received a total dose of 80 µg of neosaxitoxin in an isoosmotic solution of 0.9 % NaCl, pH 6.5. Infiltration was performed via cystoscopy under spinal anesthesia. Questionnaires were administered immediately before and 7, 30 and 90 days after the procedure to measure the patients' reported pain severity and quality of life.

Results: This study, for the first time, showed the effect of blocking the neuronal transmission of pain by local infiltration of neosaxitoxin into the bladder submucosa. All five patients successfully responded to the treatment. Furthermore, the analgesic effect lasted for the entire 90 days of follow-up without the need for a second infiltration, and no adverse reactions to neosaxitoxin were detected.

Conclusions: Neosaxitoxin infiltration was shown to be a safe and effective intervention to control pain related to BPS. It was well tolerated by patients, who experienced extended pain relief and associated beneficial effects over a follow-up of 90 days. These results confirm the effectiveness of neosaxitoxin as a long-acting local pain blocker.

Citing Articles

The Chemistry of Phytoplankton.

Liu X, Bian Z, Hu S, Dickinson C, Benjamin M, Jia J Chem Rev. 2024; 124(23):13099-13177.

PMID: 39571071 PMC: 11638913. DOI: 10.1021/acs.chemrev.4c00177.

Dinoflagellate Phosphopantetheinyl Transferase (PPTase) and Thiolation Domain Interactions Characterized Using a Modified Indigoidine Synthesizing Reporter.

Williams E, Bachvaroff T, Place A Microorganisms. 2022; 10(4).

PMID: 35456738 PMC: 9027781. DOI: 10.3390/microorganisms10040687.

An Updated Review of Tetrodotoxin and Its Peculiarities.

Katikou P, Gokbulut C, Kosker A, Campas M, Ozogul F Mar Drugs. 2022; 20(1).

PMID: 35049902 PMC: 8780202. DOI: 10.3390/md20010047.

Voltage-Gated Sodium Channels: A Prominent Target of Marine Toxins.

Mackieh R, Abou-Nader R, Wehbe R, Mattei C, Legros C, Fajloun Z Mar Drugs. 2021; 19(10).

PMID: 34677461 PMC: 8537899. DOI: 10.3390/md19100562.

Industrial Applications of Dinoflagellate Phycotoxins Based on Their Modes of Action: A Review.

Cho K, Heo J, Han J, Hong H, Jeon H, Hwang H Toxins (Basel). 2020; 12(12).

PMID: 33353166 PMC: 7766252. DOI: 10.3390/toxins12120805.

References

Ghazwani Y, Elkelini M, Hassouna M . Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011; 30(7):1271-5. DOI: 10.1002/nau.21037. View

Peters K, Feber K, Bennett R . A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. BJU Int. 2007; 100(4):835-9. DOI: 10.1111/j.1464-410X.2007.07082.x. View

Clauw D, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J . The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res. 1997; 31(1):125-31. DOI: 10.1016/s0022-3956(96)00051-9. View

OLeary M, Sant G, Fowler Jr F, Whitmore K . The interstitial cystitis symptom index and problem index. Urology. 1997; 49(5A Suppl):58-63. DOI: 10.1016/s0090-4295(99)80333-1. View

Rodriguez-Navarro A, Lagos M, Figueroa C, Garcia C, Recabal P, Silva P . Potentiation of local anesthetic activity of neosaxitoxin with bupivacaine or epinephrine: development of a long-acting pain blocker. Neurotox Res. 2009; 16(4):408-15. DOI: 10.1007/s12640-009-9092-3. View

Aihara K, Hirayama A, Tanaka N, Fujimoto K, Yoshida K, Hirao Y . Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy. Int J Urol. 2009; 16(12):947-52. DOI: 10.1111/j.1442-2042.2009.02396.x. View

Rossberger J, Fall M, Jonsson O, Peeker R . Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology. 2007; 70(4):638-42. DOI: 10.1016/j.urology.2007.05.028. View

Rodriguez-Navarro A, Berde C, Wiedmaier G, Mercado A, Garcia C, Iglesias V . Comparison of neosaxitoxin versus bupivacaine via port infiltration for postoperative analgesia following laparoscopic cholecystectomy: a randomized, double-blind trial. Reg Anesth Pain Med. 2011; 36(2):103-9. DOI: 10.1097/aap.0b013e3182030662. View

Offiah I, McMahon S, OReilly B . Interstitial cystitis/bladder pain syndrome: diagnosis and management. Int Urogynecol J. 2013; 24(8):1243-56. DOI: 10.1007/s00192-013-2057-3. View

10.

Alagiri M, Chottiner S, Ratner V, Slade D, Hanno P . Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997; 49(5A Suppl):52-7. DOI: 10.1016/s0090-4295(99)80332-x. View

11.

Garrido R, Lagos N, Lattes K, Abedrapo M, Bocic G, Cuneo A . Gonyautoxin: new treatment for healing acute and chronic anal fissures. Dis Colon Rectum. 2005; 48(2):335-40. DOI: 10.1007/s10350-004-0893-4. View

12.

Lubeck D, Whitmore K, Sant G, Lai C . Psychometric validation of the O'leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001; 57(6 Suppl 1):62-6. DOI: 10.1016/s0090-4295(01)01126-8. View

13.

Propert K, Mayer R, Wang Y, Sant G, Hanno P, Peters K . Responsiveness of symptom scales for interstitial cystitis. Urology. 2006; 67(1):55-9. DOI: 10.1016/j.urology.2005.07.014. View

14.

Lowell Parsons C . The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007; 69(4 Suppl):9-16. DOI: 10.1016/j.urology.2006.03.084. View

15.

Mangera A, Apostolidis A, Andersson K, Dasgupta P, Giannantoni A, Roehrborn C . An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2013; 65(5):981-90. DOI: 10.1016/j.eururo.2013.10.033. View

16.

Rodriguez-Navarro A, Lagos N, Lagos M, Braghetto I, Csendes A, Hamilton J . Neosaxitoxin as a local anesthetic: preliminary observations from a first human trial. Anesthesiology. 2007; 106(2):339-45. DOI: 10.1097/00000542-200702000-00023. View

17.

Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T . Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol Urodyn. 2009; 29(1):191-8. DOI: 10.1002/nau.20847. View

18.

Colaco M, Evans R . Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013; 14(5):442-7. DOI: 10.1007/s11934-013-0369-y. View

19.

Rosenberg M, Hazzard M . Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol. 2005; 174(6):2231-4. DOI: 10.1097/01.ju.0000181203.82693.95. View

20.

Seth J, Khan M, Dasgupta P, Sahai A . Botulinum toxin-what urologic uses does the data support?. Curr Urol Rep. 2013; 14(3):227-34. DOI: 10.1007/s11934-013-0326-9. View